Oct 2026· Pharmacia· Vol 73· 0 citations· 30 references
TL;DR
Therapeutic drug monitoring of UST could serve as a valuable approach for optimizing CD therapy and recommendations were made to continue treatment in 43 patients, escalate therapy or shorten the dosing interval in 20 patients, and switch to another biologic agent in 13 patients.
Abstract
Crohn’s disease (CD) is a chronic inflammatory disorder. Ustekinumab (UST) is an effective treatment for CD. Therapeutic drug monitoring (TDM) enhances clinical efficacy while minimizing side effects. This study aimed to evaluate the UST trough level (TL) and anti-drug antibodies (ADAs) and to assess the response of patients with CD to optimize UST treatment. This single-center, cross-sectional study included 76 adult patients with CD receiving maintenance UST for at least 24 weeks. The serum TL of UST and clinical remission were assessed at the same visit, immediately before the next dose. Patients were categorized into two groups: Group A, patients reaching the UST target TL (≥1 µg/mL), and Group B, patients failing to reach it. The association between UST exposure and remission was assessed by binary logistic regression. The remission rate was significantly higher in Group A (78.2%) than in Group B (28.6%) (
p
< 0.001). Based on the TL of UST, ADA positivity, and disease activity, recommendations were made to continue treatment in 43 patients, escalate therapy or shorten the dosing interval in 20 patients, and switch to another biologic agent in 13 patients. Accordingly, TDM of UST could serve as a valuable approach for optimizing CD therapy.
INTRODUCTION
Ustekinumab (UST), an anti-interleukin-12/23 antibody, is used to treat moderate-to-severe inflammatory bowel disease (IBD). The STOCUSTE study includes IBD patients treated with UST at four teaching hospitals in Stockholm to provide long-term follow-up data. The utility of therapeutic drug monitoring to o...
H. Sabhan, F. Bello, Samer Muhsen et al.· European Journal of Gastroen...· 0 citations
IL12B rs6887695 emerged as a potential pharmacogenetic marker associated with favorable ustekinumab outcomes; however, this exploratory and hypothesis-generating finding requires external validation in larger, independent cohorts before clinical application.
Ylenia Marino, M. Rottura, Claudia Ligresti et al.· Pharmaceuticals· 0 citations
BACKGROUND
Managing Crohn's disease is challenging as a substantial proportion of patients lose response to biologics. This study evaluated dual targeted therapy (DTT) with ustekinumab (UST) and vedolizumab (VDZ) in patients refractory to both agents as monotherapies.
METHODS
This retrospective study enrolled 23 pati...
Chong Lu, Tao Ling, Ya-Fang Li et al.· European Journal of Gastroen...· 0 citations
Background: Ustekinumab (UST) and vedolizumab (VDZ) are established therapies for Crohn’s disease (CD) and ulcerative colitis (UC), including in patients with prior tumour necrosis factor-alpha inhibitor (anti-TNF) failure. Trough levels (TRLs) and antidrug antibodies (ADAs) are among several factors associated with th...
Petra Nagypál, Krisztián A. Kovács, Barna Vásárhelyi et al.· Biomedicines· 0 citations
Objective This thesis investigates the differences in clinical efficacy of ustekinumab (UST) as a biologic-naïve or biologic-experienced for Crohn’s Disease (CD) patients in terms of clinical manifestations and laboratory test indicators. It also explores the correlation between clinical response status and patients’ q...
K. Yuan, Xian-Hong Hu, Qiong-Xuan Fang et al.· Frontiers in Gastroenterolog...· 0 citations
Upadacitinib was effective and well-tolerated in AT-experienced Crohn's disease, including patients with active EIMs, with induction benefit maintained through 6 months without novel safety signals.
B. Barberio, F. D'Amico, L. Laterza et al.· Alimentary Pharmacology and...· 2 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.